07/26/22 7:00 PMOTC : BRIBY covid-19Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 SubvariantsIndependent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to dateThe amubarvimab/romlusevimab combination is commercially available in China and is under reviewRHEA-AIneutral
07/19/22 12:30 AMOTC : BRIBY partnershipcovid-19Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in ChinaThe partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in ChinaThe amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, evaluated through aRHEA-AIpositive
07/13/22 7:00 AMOTC : BRIBY managementBrii Biosciences Appoints Dr. Susannah Cantrell as Chief Business OfficerBrii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovativeRHEA-AIneutral
07/06/22 7:10 PMOTC : BRIBY covid-19Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in ChinaThe Company is working closely with its commercial partners to supply the combination therapy to patients in needBrii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in less than 20 months, validating theRHEA-AIpositive
07/03/22 7:10 PMOTC : BRIBY Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater ChinaExclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBVKey partnership with Vir enables multitude of combination treatment options as part of Company's strategic approach to developing a functional cure forRHEA-AIvery positive
